Speeding up early drug development
Therapeutic molecules of clinical-grade quality. From 1 mg. Ready to ship.
Therapeutic Molecules Biologics ADCs Monoclonal antibodies Bispecific antibodies Reference products
aliquoted from medicines
best selling products
Analytical data service
Explore our comprehensive suite of analytical
methods to analyze biologic molecules.
Evidentic – fast, accurate, secure
Our products are empowering researchers worldwide
"After having great difficulty sourcing therapeutic antibodies in the small quantities required for research purposes, Evidentic has been a revelation! I have found them to be very friendly and prompt in replying to orders and queries. The online catalogue is very convenient and makes the ordering process easy and rapid. Having the products pre-reconstituted and aliquoted in a GMP Laboratory is also extremely helpful. In terms of service, delivery times and communication I rate them very highly."
Dr. Cassey McRae
Senior R&D Scientist at Avacta Life Sciences
"Evidentic gives rapid access to originator biologics and different batches. For biosimilar developers and regulators, it will shorten the time to gauge the analytical acceptance range for multiple CQAs of biotherapeutics."
Prof. Dr. Henning von Horsten
Life Science Engineering, HTW Berlin
“Evidentic was the only source that offered small aliquots of original therapeutic mAbs at an affordable price range. The aliquots came in an easy-to-use-and-store format that was apt for my research purpose.”
PhD Student ICNAS, Universidade de Coimbra
“We develop innovative and biosimilar mAbs for a global market. Evidentic’s aRMPs are a great source of cost-efficient reference products for our research and development program.”
Tom H. Jin, M.D.
Director of Process Development
"Evidentic is a new source of cost-efficient therapeutic mAbs for our immonassays. And easy to order!”
"Evidentic drug aliquots have helped us speed up our antibody characterization assays and selection of clonal cell lines. An easy and reliable source!"
Prof. (emeritus) Dr. Florian Wurm
CSO & Founder
”Evidentic can supply different batches of reference products for pre-clinical research. The quick access to the in-stock batches allows for ad-hoc ordering, keeps costs down and makes a headstart possible!”
Vice President Head of Biosimilars EMEA
“Evidentic drug aliquots have significantly reduced our development cycle time and strengthened our ability to do detailed [protein] characterization”
Dr Stephan Schultz
Team Leader of Analytics/DSP
Solubility of ADCs: influencing factors and optimization tips
The solubility of ADCs is a critical factor not only for clinical efficacy and safety, but also for manufacturability. Here, we will discuss the factors that affect the solubility of ADCs and how to optimize their solubility.
How to identify the right molecule for your assay
Why you should distinguish clinical-grade from research-grade molecules
Biologic drugs approvals in 2021
Approvals of biologic drugs from EMA and FDA include new molecular entities (NMEs), expanded therapeutic indications, new dosage forms, novel formulations, and biosimilars. In the light of COVID-19, much of the biologic EUAs pertain to vaccines and anti-viral drugs against the SARS-CoV-2 virus. In addition, a number of breakthrough innovations have been approved for rare diseases, which is consistent with the current shift towards speciality drugs in the pharma industry.
15–19 May 2023
Hynes Convention Center
900 Boylston Street
Boston, MA 02215, US
5–8 June 2023
BIO International Convention
Boston Convention & Exhibition Center
415 Summer St.
Boston, MA 02210, US
22–23 June 2023
Palais des Congrès de Tours – Tours, France
26 Bd Heurteloup
37000 Tours, France